This study investigated whether supplements containing omega-3 fatty acids, combined with GLA (gamma-linolenic acid) and vitamin D, could help treat atopic dermatitis in children. The researchers conducted a clinical trial comparing the supplement against a placebo to see if it would reduce disease severity and the need for topical corticosteroids.

The researchers conducted a 4-month randomized, triple-blind, placebo-controlled trial. Children were randomly assigned to receive either the active supplement (containing fish oil, EPA, DHA, GLA, and vitamin D) or a placebo. Disease severity was measured using the SCORAD index, and researchers tracked corticosteroid use, itching intensity, sleep quality, and quality of life measures.

The study included 52 children aged 1-8 years with moderate to severe atopic dermatitis (SCORAD >25). The children were divided into two equal groups of 26 each. Most participants had moderate atopic dermatitis, with some having severe cases. Many children also had food allergies (69.2% in intervention group, 46.2% in placebo group).

The supplement group showed significant improvements compared to placebo: - Disease severity (SCORAD) decreased from 42 to 25 in the supplement group but remained unchanged in the placebo group - Corticosteroid use decreased by 67% in the supplement group - Itching and sleep disturbance improved significantly in the supplement group - Quality of life improved for families in the supplement group

The researchers concluded that omega-3 fatty acids combined with GLA and vitamin D may be a safe and effective treatment that can reduce atopic dermatitis severity in children. The supplement helped decrease symptoms and improved the clinical picture of atopic dermatitis, suggesting it could be considered as a complementary treatment option.